Thursday, September 26, 2024
7:00 PM-8:30 PM PT
Member, American College of Lifestyle Medicine
Member, American Association for Physician Leadership
Endeavor Health Concierge Medicine
Naperville, Illinois
Urologic Oncology and Precision Medicine
Mercy Hospital St. Louis
David C. Pratt Cancer Center
St. Louis, Missouri
Director, University of Pittsburgh Medical Center (UPMC) Primary Care Precision Medicine Center
Co-Director, HUB Core: Integrating Special Populations and Community Partners Core
Clinical and Translational Science Institute (CTSI)
Institute for Precision Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania
Prefer to attend in person? Register for our live program at ExchangeCME.com/MCEDPhoenixLive.
Target Audience
The educational design of this activity addresses the needs of family practice physicians, nurse practitioners, and physician assistants.
Program Description
This CME Jeopardy™ educational activity is designed to provide an engaging and informative learning session on blood-based multi-cancer early detection (MCED) screening in the primary care setting. The program will begin with a didactic presentation of key content related to gaps and limitations of current guideline-recommended cancer screening modalities, the science and data behind MCED tests, and practical information on the potential use of MCED screening in clinical practice. After the didactic session, all learners will use their audience response system keypads to participate in a modified “Jeopardy” game in which their responses to questions about MCED screening will determine which team emerges as the winner.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the role of blood-based cancer screening in addressing the limitations of current guideline-recommended screening modalities and improving early cancer detection rates
- Explain the use of methylated cell-free DNA for the early detection of various cancer types and their tissue of origin
- Discuss recent clinical trial and real-world data on available and emerging blood-based MCED screening tests
- Integrate MCED screening into primary care practice, including patient eligibility criteria, shared decision-making, and appropriate follow-up pathways
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Continuing Medical Education
The AAFP has reviewed Testing Your Skills in Blood-Based Multi-Cancer Screening—A CME Jeopardy™ activity and deemed it acceptable for up to 1.50 Live AAFP Prescribed credit(s). Term of Approval is from 09/26/2024 to 09/26/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the live meeting/stream and complete the posttest and program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.
Disclosures of Relevant Financial Relationships
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mark D. Gomez, MD: Speakers’ Bureau: GRAIL, Inc.
Gautum Agarwal, MD, FACS: Consulting Fees: GRAIL, Inc., Natera, Tempus
Mylynda B. Massart, MD, PhD: Speakers’ Bureau: GRAIL, Inc.
The Integritas planners and managers have no relevant financial relationships with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Register Now


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Jonathan M. Hand, MD; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS |


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS; Professor Dave Singh MD, FERS, FBPhS; Jonathan M. Hand, MD |
